依达拉奉对急性进展性脑梗死疗效影响的动态观察及安全性评价

Dynamic observation and safety evaluation of edaravone on acute cerebral infarction curative effect

目的研究依达拉奉、阿司匹林和瑞舒伐他汀对急性进展性脑梗死的临床疗效、凝血指标和神经功能缺损的影响。方法将2010年9月~2014年7月100例我院收治的急性进展性脑梗死患者按随机数字表法分为对照组和治疗组各50例,对照组患者应用阿司匹林和瑞舒伐他汀治疗;治疗组患者应用依达拉奉、阿司匹林和瑞舒伐他汀治疗。在治疗后对两组患者的临床疗效和凝血指标对比,对两组患者的神经功能缺损程度进行评分比较。结果治疗组患者的临床疗效总有效率（94.0%）显著高于对照组（76.0%）,两组间差异在统计学上有意义（P〈0.05）;治疗组患者的神经功能缺损评分显著低于对照组,两组间差异有统计学意义（P〈0.05）;在治疗前后两组患者的Fib含量均低于治疗前,差异有统计学意义（P〈0.05）。结论依达拉奉联合阿司匹林和瑞舒伐他汀治疗急性进展型脑梗死的疗效显著,且无不良反应。

Objective To investigate the curative effect, blood coagulation parameters and neural function defect of edaravone,aspirin and rosuvastatinin on the patients with acute cerebral infarction. Methods 100 cases of acute progressive cerebral infarction patients in our hospital were randomly divided into the control group and the treatment group,50 cases in each group.The patients in the treatment group were given edaravone,aspirin and rosuvastatin treatment; the control group were treated with aspirin combined with rosuvastatin.After treatment the clinical curative effect and blood coagulation indexes of two groups of patients were compared,and the degree of neurological deficit scores were compared in two groups of patients. Results The clinical effect of the treatment group patients with total effective rate（94%） was significantly higher than that of the control group（76%）,and the difference between two groups was statistically significant（P〈 0.05）;neurological deficit scores in the treatment group of patients were significantly lower than that of the control group, and the difference between the two groups was statistically significant（P 〈0.05）;Fib content of two groups of patients before and after treatment were lower than those before treatment, and the difference was statistically significant（P〈 0.05）. Conclusion Edaravone, aspirin and rosuvastatin is obviously effective in the treatment of acute progressive cerebral infarction,and has no adverse reaction.